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Difficulties in the treatment of recurring diffuse alveolar 
hemorrhage accompanying primary antiphospholipid syndrome: 
a case report and literature review
Abstract
Pulmonary	embolism	 is	 the	most	common	pulmonary	manifestation	of	primary	antiphospholipid	syndrome	(PAPS).	However,	
PAPS	may	manifest	in	the	respiratory	system	also	due	to	non-thrombotic	processes.	In	the	following	paper	we	present	a case	of	
PAPS-related	diffuse	alveolar	hemorrhage	(DAH).	Because	of	sparse	literature	and	a lack	of	randomized	controlled	trials,	there	are	
currently	no	recommendations	regarding	the	optimal	choice	of	steroid-sparing	agent	in	treating	PAPS-related	DAH.	In	our	patient,	
treatment	with	cyclophosphamide	or	mycophenolate	mofetil	along	with	low	dose	prednisone	was	ineffective,	partially	because	
of	infectious	complications,	whereas	addition	of	monthly	intravenous	immunoglobulin	to	mycophenolate	mofetil	and	prednisone,	
appears	to	control	the	disease.	
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Introduction
Primary antiphospholipid syndrome (PAPS) 
is a  systemic disease associated with recur-
ring venous or arterial thrombosis and obstetric 
complications. The pathogenesis of these mani-
festations is related to the numerous effects of 
antiphospholipid antibodies (APLA) on hemosta-
sis, with the most important effect attributed to 
anti-beta 2 glycoprotein 1 antibodies [1]. APLA 
are also reported to interfere with endothelial cell 
metabolism, platelet function, monocytes, and 
neutrophils. Furthermore, increases in oxidative 
stress and tissue factor generation along with 
activation of the complement system were noted 
[1]. PAPS, however, does not manifest exclusively 
with thrombotic symptoms. Other manifestations 
such as diffuse alveolar hemorrhage (DAH), Li-
bman-Sacks endocarditis or chorea cannot be 
easily linked to the influence of APLA on blood 
coagulation [2]. Diffuse alveolar hemorrhage 
(DAH), which may be the first or isolated symp-
tom in PAPS/APLA positive patients [3–6], is 
a clinical syndrome of multi-causal pathological 
background. As DAH symptoms are a  result of 
an erythrocyte accumulation in the alveolar air 
space, most common features are diffuse bilateral 
airspace opacities on radiological examination, 
hypoxemic respiratory failure, anemia, and he-
moptysis. Herein, we present a difficult to control 
case of PAPS-related DAH. 
Case report
A 47-year-old Caucasian man was admitted 
to the hospital in December 2013 because of 
increasing dyspnea and hemoptysis, which had 
developed two days earlier. His medical history 
included PAPS, which had manifested as a deep 
venous thrombosis and pulmonary emboli, for 
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Table 1. Laboratory Tests in December 2013
CRP 47.35	mg/L
PCT 0.1	ng/mL
WBC 7.85	G/L
HGB 10.4	g/dL
PLT 250	G/L
INR 2.23
D-dimer 217	µg/L	FEU
Cr 1.65	mg/dL
BNP 10	pg/mL
ANA-Hep2 1:160
ANCA (–)
AECA (–)
Anti-GBM (–)
C3 0.85	g/L
C4 0.06	g/L
CRP:	 C-reactive	 protein;	 PCT:	 procalcitonin;	 WBC:	 white	 blood	 cells;	 HGB:	
hemoglobin;	PLT:	platelets;	 INR:	 international	normalized	 ratio;	Cr:	creatinine;	
BNP:	brain	natriuretic	peptide;	ANA-Hep2:	anti-nuclear	antibodies	Hep2;	ANCA:	
anti-neutrophil	cytoplasmic	antibodies;	AECA:	anti-endothelial	cell	antibodies;	
Anti-GBM:	anti-glomerular	basement	membrane	antibodies;	C3:	 complement	
component	3;	C4:	complement	component	4
Figure 1.	 Chest	 radiogram	 obtained	 two	 days	 before	 admission	 in	
December	2013	showing	patchy	alveolar	infiltrates	in	the	middle	and	
lower	parts	of	the	lungs
which warfarin was administered. Diagnosis met 
the revised Sapporo criteria [7]. Several months 
prior he had transient hearing loss, another 
possible PAPS manifestation [8], which resolved 
with glucocorticosteroids (GCS). Furthermore, 
he had a history of chronic renal disease and 
asthma. On admission, the patient was afebrile, 
normotensive (140/86 mm Hg), and not tachy-
cardic (90 per minute). Auscultation of the lung 
revealed bilateral rales above the lower lungs, 
and wheezing. Arterial blood gas analysis showed 
hypoxemia (pO2 = 57 mm Hg). Laboratory results 
(Table 1) revealed increased C-reactive protein 
level (47.35 mg/L); however, the procalcitonin 
level and white blood cell count were within the 
normal range. Hemoglobin level was 10.4 g/dL. 
International normalized ratio (INR) was within 
the therapeutic range (2.23) and the D-dimer level 
was low (217 µg/L FEU). The elevated creatinine 
levels (1.46–1.74 mg/dL) were stable in compari-
son to previous laboratory tests. Chest radiograph 
showed bilateral patchy alveolar infiltrates in 
the middle and lower parts of the lungs (Fig. 1). 
Echocardiogram did not reveal any structural 
abnormalities; right ventricular systolic pressure 
was not elevated, and the ejection fraction was 
60%. The high resolution computed tomography 
(HRCT) showed extensive bilateral ground-glass 
opacities (GGO) disseminated in the upper and 
lower lobes (Fig. 2). Bronchofiberoscopy did not 
reveal any pathology within the bronchial tree. 
Furthermore, the analysis of bronchoalveolar la-
vage fluid (BALF) samples for potential neoplasms 
or infections (including cytology, bacterial and 
fungal cultures), acid-fast bacilli smear and myco-
bacterial growth indicator tube cultures, immuno-
fluorescence assay for Pneumocystis jiroveci cysts 
(PCPIF), and serum mannan and galactomannan 
antigen tests were negative. However, during 
BALF collection, progressively more hemorrhagic 
aliquots were obtained. BALF cytology revealed 
Figure 2.	 High	 resolution	 computed	 tomography	 at	 admission	 in	
December	 2013	 showing	 extensive	 bilateral	 ground-glass	 opacities	
(GGO)
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Table 2. Course of treatment
12.2013 First	DAH	episode:	
•	 Three	MTP	pulses	(750→1000→1000	mg)	
•	 80	mg	prednisone	
01.2014-
07.2014
•	 Prednisone	in	tapering	dosage	(80→20	mg)
•	 Six	CYC	pulses,	1.5g	each
08.2014 Second	DAH	episode:	
•	 Three	MTP	pulses	(500	mg	each)
•	 IVIG	(5	×	50	g)
•	 60	mg	prednisone	
08.2014-
02.2015
•	 Prednisone	in	a	tapering	dosage	(55→25	mg)
•	 MMF	(1	g	daily)	
02.2015 Third	DAH	episode:	
•	 100	mg	prednisone	
•	 2	g	MMF
02.2015-
04.2015
•	 Prednisone	in	a	tapering	dosage	(90→75	mg)
•	 MMF	(2	g	daily)	
04.2015	 Pneumonia	and	fourth	DAH	episode:	
•	 75	mg	Prednisone	
•	 MMF	(2	g	daily)	
04.2015–
05.2016
•	 Prednisone	in	a	tapering	dosage	(65→15	mg)
•	 MMF	(2	g	daily)
05.2016 Fifth	DAH	episode
•	 40	mg	Prednisone	
•	 MMF	(2	g	daily)	
05.2016–
08.2016
•	 Prednisone	in	a	tapering	dosage	(40→20	mg)
•	 MMF	(2	g	daily)	
08.2016 VKA	overdose
•	 30	mg	Prednisone	
•	 MMF	(2	g	daily)
08.2016–
10.2016
•	 Prednisone	in	a	tapering	dosage	(30→25	mg)
•	 MMF	(2	g	daily)	
10.2016–
01.2017
•	 Prednisone	in	a	tapering	dosage	(25→20	mg)
•	 MMF	(3	g	daily)	
01.2017 Sixth	DAH	episode:	
•	 Three	MTP	pulses	(500→1000→1000	mg)
•	 80mg	prednisone	
•	 IVIG	(1	×	30	g+3	×	50	g)
01.2017–
01.2018
•	 Prednisone	in	a	tapering	dosage	(50→20	mg)
•	 MMF	(3	g	daily)
•	 IVIG	(150	g	monthly)	
02.2018–
04.2018
•	 Prednisone	(20	mg)
•	 MMF	(3	g	daily)
•	 IVIG	(60	g	monthly)	
DAH:	diffuse	alveolar	hemorrhage;	MTP:	methylprednisolone;	CYC:	cyclopho-
sphamide;	IVIG:	intravenous	immunoglobulin;	MMF:	mycophenolate	mofetil
a high count of hemosiderin-laden macrophages 
(HLM), while the cell count differential was neu-
trophilic (49%) supporting the diagnosis of DAH. 
Owing to the increased risk of complications, the 
patient was not referred to surgical lung biopsy for 
a pathological confirmation of the diagnosis. The 
treatment consisted of three methylprednisolone 
pulses with increasing dosage (750 mg, 1000 mg, 
1000 mg), antibiotics (amoxicillin with clavulanic 
acid and clarithromycin), and antifungal agent 
(fluconazole). Simultaneously, anticoagulation 
therapy was temporarily discontinued. Methyl-
prednisolone (MTP) was then switched to 80 mg 
oral prednisone daily. The treatment resulted in 
significant improvement of dyspnea. To prevent 
thrombotic complications, warfarin was promptly 
reintroduced. 
During hospitalization an extensive wor-
kup was performed to exclude non-PAPS-rela-
ted potential causes of DAH, including syste-
mic vasculitides and connective tissue diseases 
(CTD). Complement components C3 and C4 
levels were slightly below the normal range (0.85 
G/L; 0.06 G/L, respectively), whereas laboratory 
assays for antineutrophil cytoplasm antibodies 
(ANCA), antinuclear antibodies with HEp-2 cells 
(ANA-HEp2), anti-endothelial cell antibodies, and 
anti-glomerular basement membrane antibodies 
were negative. In addition, the patient did not 
report any clinical symptoms typical for CTD or 
systemic vasculitis. APLA titers were high (anti-
cardiolipin and anti-beta2-glicoprotein antibodies 
values exceeded the upper reference limits). Re-
trospective analysis of the disease course revealed 
that he had previously experienced incidents of 
hemoptysis associated with multifocal GGO on 
HRCT with normal results on CT angiography, 
which had been interpreted at the time as due to 
an overdose of oral anticoagulants.
To maintain remission, cyclophosphamide 
(CYC) treatment along with prednisone in a tape-
ring dosage was implemented. Within the first se-
ven months of treatment, the patient received six 
1.5 g CYC pulses every four weeks. In the eighth 
month of treatment, another acute DAH episode 
occurred, which was controlled by MTP (500 mg 
daily for 3 days) and intravenous immunoglobu-
lin (IVIG; 50 g daily for 5 days). CYC treatment 
was replaced with MMF, along with prednisone, 
which provided only partial disease control 
during the following 29 months. DAH relapsed 
3 times in this period, however, due to progres-
sively milder course of DAH episodes (Table 2), 
with fourth one triggered by pneumonia, pos-
sibly a complication of high GCS dose (75 mg), 
and with fifth one diagnosed accidentally after 
routine HRCT, MMF was sustained and its dose 
gradually increased up to 3 g daily. MMF treat-
ment permitted significant GCS dose reduction 
(periodically down to 15 mg) but despite that 
patient experienced multiple, pathological rib and 
vertebrae fractures. Although bone density values 
were normal, glucocorticoid-induced osteoporo-
sis and vitamin D insufficiency were recognized 
and proper treatment was commenced. 
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In January 2017, while on 20 mg prednisone 
and 3 g MMF daily, patient experienced sixth 
DAH. Because of its severe course, including 
respiratory failure and hemoptysis, three pulses 
of MTP (500, 1000, 1000 mg) were required along 
with IVIG (180 g). Afterwards monthly IVIG (150 g 
for 12 months, 60 g afterwards) was added to 
3 g MMF along with prednisone in a  tapering 
dosage which resulted in 16 months of disease 
stabilization. 
Discussion
The etiology of DAH in PAPS is uncertain. 
One postulated mechanism involves capillaritis, 
which develops in a “two-hit” model [3], simi-
lar to a proposed mechanism of thrombosis in 
APS [9]. This hypothesis assumes that APLA, 
which influence the expression of pro-adhesive 
molecules on the surface of endothelial cells [1], 
are responsible for the “first hit”. Other factors 
affecting endothelial cell activity, particularly 
those upregulating the adhesion molecules (such 
as infection or trauma), comprise the “second 
hit” resulting in neutrophil infiltration, vascular 
inflammation, and destruction of the alveolar 
septae. Unfortunately, not all patients who pre-
sent with DAH in a PAPS/APLA setting actually 
exhibit neutrophilic vasculitis on pathologic 
examination. Yachoui et al. [4] published a case 
series report in which only one out of six patients 
subjected to lung biopsy showed neutrophilic 
infiltration, while the remaining five presented as 
bland hemorrhage [4]. Others have underlined [2] 
that neutrophilic interstitial infiltration alone, [3, 
4, 10, 11] without perivascular or vascular infil-
trates does not allow for recognizing vasculitis. 
However, lack of these features does not allow for 
a virtual ruling out of vasculitis because histologi-
cal findings may vary depending on both the lung 
region and the activity of the disease [12]. On the 
other hand, to date, there have been only single 
case studies describing PAPS-related vasculitis 
in non-pulmonary systems [13]. Nevertheless, 
APLA-mediated pulmonary vasculitis may be 
a result of unique features of the lung, including 
a  large endothelium surface area in relatively 
narrow capillaries that are positioned on a border 
with an environment rich in various stimuli [3]. 
Due to the inconsistencies in the vasculitis 
model, it has been suggested that DAH may be 
a result of complement system activation media-
ted by APLA [2], as it is postulated in obstetric 
APS [1]. This hypothesis is mainly based on 
studies on mice showing that complement fac-
tor C2 mediates the neutrophilic infiltration and 
destruction of lung tissue after reperfusion of an 
ischemically injured gastrointestinal tract, most 
likely through the lectin pathway, of which C2 is 
an important part [2]. The lectin pathway might 
be activated by L-ficolin, which binds gram po-
sitive bacteria and is synthesized in the lung by 
type 2 pneumocytes and bronchial epithelium. 
Another study has shown that both murine 
and human APLA injected into complement 
receptor 2-deficient mice reconstitute ischemia/ 
/reperfusion damage locally in the intestines and 
remotely in the lungs [2]. 
There are certain similarities between our 
case and those previously described in the lite-
rature. Our patient is a male [3–6, 10, 11], in the 
fourth decade of life [3, 4, 6, 10, 11], with a neu-
trophilic (49%) BALF [4, 10] and high APLA titer 
[3–5, 10, 11]. Due to lack of the histopathological 
examination and normal bone density values, we 
cannot dismiss that pathological fractures, which 
our patient experienced, were a result of osteone-
crosis, reported in other patients with PAPS as 
well [2]. Scheiman et al. [11] compared a group 
of 13 patients with pulmonary hemorrhage (PH) 
and secondary or primary APS to patients with 
APS without PH and showed that the former 
were more likely to experience non-thrombotic 
complications of APS, had a higher titer of APLA 
and a higher rate of pregnancy morbidity. Since 
the clinical presentation of non-thrombotic mani-
festations of PAPS is variable, Asherson et al. [2] 
speculated that there may be multiple subtypes of 
APLA, each with a different specificity, resulting 
in different symptoms. 
The initial standard treatment of DAH inc-
ludes GCS, typically either intravenous methyl-
prednisolone or oral prednisone, depending on 
the severity of the episode. It should be noted that 
DAH symptoms may be mild enough to be over-
looked in a proportion of patients. As reported by 
Yachoui et al. [4], such patients may experience 
complete and sustained remission without any 
immunosuppression. Moreover, not all patients 
will develop a relapse and require long-term tre-
atment [6]. In our case, owing to recurrent disease 
and a high risk of new DAH episodes, we decided 
to start with CYC treatment. Although there are 
currently no randomized trials to support any 
recommendations regarding the choice of a ste-
roid-sparing drug, CYC has been used effectively 
in vasculitides such as granulomatosis with poly-
angiitis and is suggested, along with rituximab, 
to be one of the most effective steroid-sparing 
agents in this setting [3, 4, 10]. However, CYC 
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treatment failed to maintain remission in our 
patient. Switching to MMF also did not provide 
full control of the disease. Following the sixth 
DAH episode monthly IVIG was agreed upon. 
IVIG theoretically provides some advantages 
over immunosuppressant drugs. Its approved 
usage in primary and acquired immunodefi-
ciencies can translate into protecting PAPS 
patients from infections which may, as in our 
patient, trigger DAH. Furthermore IVIG is an 
important part of catastrophic APS treatment 
and has been shown to be useful in preventing 
recurrent thrombotic incidents and obstetric 
complications of APS [14]. Despite this strong 
rationale behind its use, previous experien-
ces with IVIG are mixed. Deane et al. [3] and 
Gertner et al. [6] described 3 patients who 
achieved disease control with IVIG, whereas 
other authors [10, 15] reported 6 patients who 
did not. In our patient adding IVIG allowed for 
16 months of stabilization.
Other treatments explored in this setting, 
with mixed results, are: azathioprine [4, 5, 10], 
methotrexate [4], hydroxychloroquine [3, 4] and 
plasmapheresis [4, 5, 10]. 
Conclusions
Hemoptysis and dyspnea in PAPS require 
careful assessment. Pulmonary consultation 
along with bronchofiberoscopy should always be 
considered. A DAH diagnosis should be followed 
by an initial treatment consisting of high doses 
of GCS. There are currently no recommendations 
regarding the choice of steroid-sparing agent for 
long-term treatment. In our patient combined 
treatment, CYC or MMF with GCS, did not result 
in long-lasting remission and DAH reoccurred. As 
yet, the disease remains controlled after adding 
monthly IVIG to MMF and GCS. In our opinion it 
is worth considering adding IVIG to treatment of 
patients with recurrent infectious complications 
of immunosuppressive therapy. 
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